Plus Therapeutics, Inc.
PSTV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.5% | 31.3% | -25% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.8% | 93.8% | 82.9% | 83.6% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -310.5% | 379.3% | -1,271.1% | -255.9% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -316.6% | 370.6% | -1,643.2% | -276.4% |
| EPS Diluted | -0.04 | -0.007 | -1.19 | -0.66 |
| % Growth | -515.4% | 99.5% | -80.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |